Interleukin 17 Blockade in Psoriasis Patients with Subclinical Joint Inflammation- Prospective Open Study to Influence the Course of the Disease by means of Secukinumab

Kampylafka E, Oliveira I, Linz C, Lerchen V, Englbrecht M, Simon D, Rech J, Kleyer A, Schett G, Sticherling M, Hueber A (2019)

Publication Type: Conference contribution

Publication year: 2019

Journal

Journal der Deutschen Dermatologischen Gesellschaft Wiley-Blackwell

Publisher: WILEY

City/Town: HOBOKEN

Pages Range: 127-128

Conference Proceedings Title: JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT

Authors with CRIS profile

Matthias Englbrecht Lehrstuhl für Innere Medizin III David Simon Department of Medicine 3 – Rheumatology and Immunology Hans Jürgen Rech Department of Medicine 3 – Rheumatology and Immunology Arnd Kleyer Department of Medicine 3 – Rheumatology and Immunology Georg Schett Lehrstuhl für Innere Medizin III Michael Sticherling Professur für Dermatologie Axel Hueber Department of Medicine 3 – Rheumatology and Immunology

How to cite

APA:

Kampylafka, E., Oliveira, I., Linz, C., Lerchen, V., Englbrecht, M., Simon, D.,... Hueber, A. (2019). Interleukin 17 Blockade in Psoriasis Patients with Subclinical Joint Inflammation- Prospective Open Study to Influence the Course of the Disease by means of Secukinumab. In JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (pp. 127-128). HOBOKEN: WILEY.

MLA:

Kampylafka, E., et al. "Interleukin 17 Blockade in Psoriasis Patients with Subclinical Joint Inflammation- Prospective Open Study to Influence the Course of the Disease by means of Secukinumab." Proceedings of the JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT HOBOKEN: WILEY, 2019. 127-128.

BibTeX: Download